Connor, Clark & Lunn Investment Management (CC&L)’s Lexicon Pharmaceuticals LXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-282,467
| Closed | -$432K | – | 1638 |
|
|
2023
Q4 | $432K | Sell |
282,467
-54,597
| -16% | -$83.5K | ﹤0.01% | 1085 |
|
|
2023
Q3 | $367K | Buy |
337,064
+2,813
| +0.8% | +$3.07K | ﹤0.01% | 1095 |
|
|
2023
Q2 | $765K | Buy |
334,251
+125,918
| +60% | +$288K | ﹤0.01% | 875 |
|
|
2023
Q1 | $506K | Buy |
208,333
+73,776
| +55% | +$179K | ﹤0.01% | 873 |
|
|
2022
Q4 | $257K | Buy |
+134,557
| New | +$257K | ﹤0.01% | 1006 |
|
|
2021
Q1 | – | Sell |
-48,249
| Closed | -$165K | – | 1041 |
|
|
2020
Q4 | $165K | Sell |
48,249
-62,014
| -56% | -$212K | ﹤0.01% | 839 |
|
|
2020
Q3 | $159K | Buy |
110,263
+39,352
| +55% | +$56.7K | ﹤0.01% | 857 |
|
|
2020
Q2 | $141K | Buy |
70,911
+27,211
| +62% | +$54.1K | ﹤0.01% | 930 |
|
|
2020
Q1 | $85K | Buy |
+43,700
| New | +$85K | ﹤0.01% | 946 |
|
|
2018
Q1 | – | Sell |
-40,575
| Closed | -$401K | – | 765 |
|
|
2017
Q4 | $401K | Buy |
40,575
+28,000
| +223% | +$277K | ﹤0.01% | 652 |
|
|
2017
Q3 | $155K | Buy |
+12,575
| New | +$155K | ﹤0.01% | 768 |
|